tazobactam has been researched along with avibactam in 30 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (avibactam) | Trials (avibactam) | Recent Studies (post-2010) (avibactam) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 360 | 16 | 352 |
| Protein | Taxonomy | tazobactam (IC50) | avibactam (IC50) |
|---|---|---|---|
| Beta-lactamase | Enterobacter cloacae | 0.1 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 0.128 | |
| Beta-lactamase TEM | Escherichia coli | 0.0019 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 18 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, MT; Bruneau, JM; Claudon, M; Coleman, K; Frère, JM; Miossec, C; Péchereau, MC; Stachyra, T | 1 |
| Benvenuti, M; Burns, CJ; Chu, GH; Cusick, SM; Daigle, DM; De Luca, F; Docquier, JD; Hamrick, JC; Jackson, RW; Liu, B; Mangani, S; McGarry, D; Pevear, DC; Pozzi, C; Trout, REL; Weiss, WJ; Xerri, L | 1 |
| Baumert, P; Feihl, S; Gastmeier, P; Gebhardt, F; Gölz, H; Hamprecht, A; Kern, WV; Knobloch, J; Kola, A; Mischnik, A; Obermann, B; Peter, S; Querbach, C; Rohde, A; Seifert, H; Tacconelli, E; Willmann, M | 1 |
| Benier, L; Bodrenko, I; Ceccarelli, M; Ghai, I; Pira, A; Scorciapino, MA; Wagner, R; Winterhalter, M | 1 |
| Monogue, ML; Nicolau, DP; Nizet, V; Sakoulas, G | 1 |
| Amicosante, G; Conte, V; Giani, T; Perilli, M; Piccirilli, A; Rossolini, GM; Tascini, C | 1 |
| Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L | 1 |
| Blok, A; Pannu, NS; Tassoni, R; Ubbink, M | 1 |
| Abodakpi, H; Byerly, C; Chang, KT; Tam, VH; Zhou, J | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Humphries, RM; Spafford, K | 1 |
| Bonomo, RA; Evans, SR | 1 |
| Baklouti, S; Concordet, D; Gandia, P; Guet-Revillet, H; Mane, C; Massip, C; Murris, M | 1 |
| Aboklaish, AF; Brem, J; Jackson, DE; Langley, GW; Schofield, CJ; Tselepis, L; Tyrrell, JM; Walsh, TR; Widlake, E | 1 |
| Bacca, E; Bedini, A; Bianco, V; Cuomo, G; Franconi, I; Meschiari, M; Mussini, C; Orlando, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Oliver, A; Rodiño-Janeiro, BK; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF | 1 |
| Bauer, T; Berbescu, S; Bouchand, F; Davido, B; de Laroche, M; Dinh, A; Duran, C; Matt, M; Nich, C; Noussair, L; Pagis, V; Rempenault, C; Rottman, M; Salomon, E | 1 |
| Gatermann, SG; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N | 1 |
| Daragon, B; Fournier, D; Jeannot, K; Plésiat, P | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Meesing, A; Sribenjalux, W; Wonglakorn, L | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-Pérez, B; Fraile-Ribot, PA; Gato, E; González-Bello, C; Guijarro-Sánchez, P; Gutiérrez-Urbón, JM; Lasarte-Monterrubio, C; Oliver, A; Oviaño, M; Ruedas-López, A; Vallejo, JA; Vázquez-Ucha, JC; Velasco, D | 1 |
| Carvalhaes, CG; Castanheria, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
| Baretta, V; Calore, E; Carraro, F; Cesaro, S; Colombini, A; Meazza, C; Muggeo, P; Onofrillo, D; Perruccio, K; Rosaria D'Amico, M; Zama, D | 1 |
| Gill, CM; Nicolau, DP | 2 |
| Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R | 1 |
| Hsueh, PR; Lee, YL | 1 |
2 review(s) available for tazobactam and avibactam
| Article | Year |
|---|---|
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
28 other study(ies) available for tazobactam and avibactam
| Article | Year |
|---|---|
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Inhibitory Concentration 50; Molecular Structure; Spectrometry, Mass, Electrospray Ionization | 2010 |
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; Borinic Acids; Carbapenems; Carboxylic Acids; Humans; Mice; Models, Molecular | 2020 |
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Cephalosporin Resistance; Cephalosporins; Clavulanic Acid; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Germany; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2017 |
General Method to Determine the Flux of Charged Molecules through Nanopores Applied to β-Lactamase Inhibitors and OmpF.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Membrane Potentials; Molecular Dynamics Simulation; Nanopores; Penicillanic Acid; Sulbactam; Tazobactam | 2017 |
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Lung; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Thigh | 2018 |
TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Escherichia coli; Humans; Kinetics; Microbial Sensitivity Tests; Sequence Alignment; Tazobactam | 2018 |
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
Topics: Acylation; Aldehydes; Amino Acid Substitution; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Catalytic Domain; Clavulanic Acid; Crystallography, X-Ray; Mycobacterium tuberculosis; Protein Conformation; Serine; Sulbactam; Tazobactam | 2019 |
A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Dose-Response Relationship, Drug; Drug Synergism; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2019 |
Letter to the Editor.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Reply to Humphrey and Spafford.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients
Topics: Azabicyclo Compounds; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Tazobactam | 2019 |
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cefepime; Drug Combinations; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Tazobactam; Triazoles | 2020 |
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
The activity of ceftazidime/avibactam against carbapenem-resistant
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study.
Topics: Aged; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2021 |
In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Germany; Humans; Pseudomonas aeruginosa; Tazobactam | 2021 |
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.
Topics: Azabicyclo Compounds; Burkholderia pseudomallei; Ceftazidime; Cephalosporins; Humans; Melioidosis; Pseudomonas aeruginosa; Tazobactam; Thailand | 2022 |
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cyclooctanes; Enterobacteriaceae; Gram-Negative Bacteria; Hydrazines; Lactams; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam | 2022 |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |